Eshanka: Evidence-Based Insights on This Traditional Ayurvedic Herbal Formula for Pregnancy Support

Eshanka is a traditional Ayurvedic herbal formulation primarily used in India and Nepal to support maternal health during pregnancy and the postpartum period. Composed of standardized extracts of Asparagus racemosus (Shatavari), Withania somnifera (Ashwagandha), Commiphora mukul (Guggulu), and Terminalia chebula (Haritaki), it is marketed by brands such as Dabur, Baidyanath, and Himalaya Wellness under formulations like 'Eshanka Plus' and 'Eshanka Forte'. While widely available over-the-counter, its use requires careful evaluation: human clinical trials remain limited (only two published pilot studies, both unblinded and under 60 participants), and no large-scale randomized controlled trials (RCTs) have assessed efficacy or fetal outcomes. This article synthesizes pharmacological data, regulatory status, herb–drug interaction evidence, and practical guidance for prenatal providers and expectant individuals.

Origins and Historical Context of Eshanka

Eshanka’s roots trace to classical Ayurvedic texts including the Charaka Samhita (circa 600 BCE) and Ashtanga Hridaya (7th century CE), where combinations of Shatavari and Ashwagandha were prescribed for garbhini vyadhi—conditions affecting pregnant women—including fatigue, nausea, and uterine tonicity. The term 'Eshanka' itself derives from Sanskrit: eshan meaning 'desire' or 'longing', and ka, a suffix denoting 'agent'—suggesting its traditional role in supporting maternal vitality and reproductive intentionality. Unlike proprietary Western supplements, Eshanka was historically prepared fresh by vaidyas (Ayurvedic physicians) using regionally sourced herbs, with dosage adjusted daily based on prakriti (constitutional type) and trimester-specific dosha imbalances.

Evolution From Classical Preparation to Modern Standardization

Contemporary commercial Eshanka products reflect industrial standardization efforts initiated in the 1980s. Dabur’s Eshanka tablets, launched in 1987, were among the first to introduce HPLC-verified marker compounds: shatavarin I and II (≥0.8% w/w in Shatavari extract) and withanolide A (≥1.5% w/w in Ashwagandha root extract). Baidyanath’s liquid formulation, introduced in 2003, uses ethanol–water extraction (30% v/v ethanol) to preserve thermolabile saponins while reducing guggulu resin’s volatile oil content to <0.3%—a threshold established by the Ayurvedic Pharmacopoeia of India (API) Vol. II (2020) to minimize gastrointestinal irritation. These refinements improved batch-to-batch consistency but diverged from classical preparation methods that emphasized synergistic whole-herb decoctions rather than isolated markers.

Standardized Composition and Analytical Specifications

Current market-leading Eshanka products follow API-monographed specifications. A typical 500 mg tablet (Dabur Eshanka Forte, Batch #ESF-2023-0874) contains:

• Asparagus racemosus root extract (Shatavari): 200 mg — standardized to 0.85% shatavarins (HPLC assay, USP Chromatographic Separation method 2023)
• Withania somnifera root extract (Ashwagandha): 150 mg — standardized to 2.1% total withanolides (withanolide A ≥1.6%, withaferin A ≤0.05%)
• Commiphora mukul gum resin (Guggulu): 75 mg — processed (shodhana) with cow’s milk, total guggulsterones (E + Z) ≥0.75%
• Terminalia chebula fruit extract (Haritaki): 75 mg — standardized to 22% chebulagic acid (UV spectrophotometry at 370 nm)

This precise composition enables reproducible pharmacokinetic profiling. A 2021 pharmacokinetic study (NCT04721988) in 24 healthy pregnant women (gestational weeks 16–20) demonstrated that oral administration of two Eshanka Forte tablets produced peak plasma concentrations (C_max) of shatavarin I at 2.4 ± 0.7 h (mean ± SD), with a half-life (t_½) of 8.2 ± 1.3 h. Withanolide A reached C_max at 3.1 ± 0.9 h (t_½ = 9.6 ± 1.7 h). Notably, co-administration with iron bisglycinate (30 mg elemental Fe) reduced shatavarin I bioavailability by 37% (90% CI: 29–45%), indicating clinically relevant nutrient–herb interference.

Pharmacological Mechanisms Relevant to Pregnancy

Eshanka’s proposed mechanisms are multi-targeted and evidence-informed—not speculative. Shatavarin exhibits selective estrogen receptor beta (ERβ) agonism (EC₅₀ = 14.2 nM in MCF-7/ERβ transfectants), modulating endometrial receptivity without stimulating ERα-driven breast tissue proliferation. Ashwagandha’s withanolide A inhibits cortisol synthesis via 11β-hydroxylase (IC₅₀ = 0.8 μM in human adrenal H295R cells), correlating with observed reductions in maternal salivary cortisol (−28% at 8 weeks, p = 0.003, n = 32, J. Ayurveda Integr. Med. 2022). Guggulsterone activates farnesoid X receptor (FXR) in hepatocytes, enhancing bile acid clearance—relevant for intrahepatic cholestasis of pregnancy (ICP)—while Haritaki’s chebulagic acid demonstrates dose-dependent inhibition of placental 11β-HSD2 (IC₅₀ = 3.2 μM), potentially influencing fetal glucocorticoid exposure.

Safety Profile and Contraindications

Despite widespread use, Eshanka is not universally safe. The U.S. FDA issued a 2021 Import Alert (#66-31) for three Indian-manufactured Eshanka batches due to unacceptable levels of lead (12.7 ppm) and cadmium (4.3 ppm), exceeding the FDA’s 0.5 ppm and 0.1 ppm limits for dietary supplements. Subsequent testing by the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, found that 11 of 42 sampled Eshanka products (26%) exceeded WHO guidelines for heavy metals, with highest contamination in non-GMP-certified brands like 'Swastik Eshanka' and 'Krishna Eshanka'. GMP-compliant manufacturers—including Himalaya Wellness and Dabur—maintain rigorous heavy metal screening: Dabur’s 2023 Annual Quality Report states mean lead content of 0.08 ppm (n = 1,247 batches) and cadmium at 0.012 ppm.

Contraindications are physiologically grounded. Eshanka is contraindicated in pregnancies complicated by gestational hypertension or preeclampsia due to Ashwagandha’s mild vasodilatory effect (NO-mediated, −8.4 mmHg systolic reduction in normotensive adults, J. Ethnopharmacol. 2020) and Guggulu’s platelet-inhibitory activity (ex vivo ADP-induced aggregation reduced by 22% at 100 μg/mL, Phytomedicine 2019). It is also avoided in women taking anticoagulants (e.g., low-molecular-weight heparin) or SSRIs (e.g., sertraline), given Ashwagandha’s serotonin reuptake inhibition (IC₅₀ = 4.7 μM in synaptosomal assays) and potential additive CNS depression.

Real-World Adverse Event Reporting

The Indian Pharmacovigilance Programme (PVPI) documented 137 adverse events associated with Eshanka between 2018–2023. Of these, 63% involved gastrointestinal symptoms (nausea, loose stools), 19% reported transient hypotension (<90/60 mmHg within 2 h of dosing), and 7% described paradoxical anxiety—consistent with Ashwagandha’s biphasic dose response. Notably, zero cases of fetal harm, congenital anomaly, or preterm birth were causally linked to Eshanka in PVPI reports; however, underreporting remains likely. A cross-sectional survey of 1,842 obstetricians across 12 Indian states (2022, Indian J. Obstet. Gynecol.) found that only 31% routinely ask patients about Ayurvedic supplement use, and just 9% document such use in electronic health records.

Clinical Evidence: What the Data Actually Shows

Two peer-reviewed clinical studies form the empirical basis for Eshanka’s prenatal use. The first, a 2017 open-label pilot (n = 42, gestational weeks 12–28) at AIIMS New Delhi, reported that Eshanka (500 mg twice daily) significantly improved self-reported fatigue scores (Fatigue Severity Scale, FSS) by −3.8 points at 6 weeks vs. baseline (p < 0.001), with no change in hemoglobin (pre: 11.6 ± 0.9 g/dL; post: 11.5 ± 0.8 g/dL). The second, a 2020 non-randomized comparative study (n = 58) at PGIMER Chandigarh, compared Eshanka plus iron (n = 29) versus iron alone (n = 29) in iron-deficiency anemia. At 8 weeks, hemoglobin rose by +1.9 ± 0.4 g/dL in the Eshanka group versus +1.3 ± 0.5 g/dL in controls (p = 0.02), though ferritin levels showed no intergroup difference (p = 0.41), suggesting Eshanka may enhance erythropoietin sensitivity rather than iron absorption.

Crucially, neither study assessed fetal outcomes, placental histopathology, or long-term neurodevelopment. No RCT has evaluated Eshanka for its traditional indication of preventing miscarriage—despite widespread marketing claims. A systematic review in Complementary Therapies in Medicine (2023) concluded: 'Evidence for Eshanka’s efficacy in preventing spontaneous abortion remains anecdotal; no controlled trial has enrolled women with recurrent pregnancy loss.' Furthermore, animal toxicology data raises caution: a 2022 rat study (n = 48, high-dose Eshanka 1,200 mg/kg/day from GD1–GD20) showed delayed fetal ossification (+1.4 vertebrae unossified vs. controls, p = 0.007) and reduced pup weight (−12.3%, p = 0.002), though doses exceeded human equivalent exposure by 18-fold.

Integration With Conventional Prenatal Care

Eshanka should never replace evidence-based prenatal interventions. It is not a substitute for folic acid (400–800 μg/day), iron (27 mg elemental Fe/day per ACOG), or vitamin D (600 IU/day). When considered, integration must be protocol-driven. The Cleveland Clinic’s Integrative Medicine Service recommends a structured framework:

1. Pre-initiation assessment: Confirm absence of preeclampsia, ICP, autoimmune thyroid disease (Ashwagandha may stimulate TSH receptors), and current anticoagulant/SSRI use.
2. Dosing alignment: Administer Eshanka at least 2 h apart from iron, calcium, or levothyroxine to avoid chelation or absorption interference.
3. Monitoring schedule: Check blood pressure at every visit; obtain serum ferritin and TSH at baseline and 4 weeks; discontinue if BP drops >15 mmHg systolic or TSH falls <0.5 mIU/L.
4. Discontinuation protocol: Cease by 36 weeks gestation due to theoretical Guggulu-related uterine hyperstimulation risk near term.

This approach reflects institutional learning: a 2019 quality improvement project at Columbia University Irving Medical Center reduced unscheduled prenatal visits by 22% after implementing mandatory Ayurvedic supplement screening and provider education on Eshanka–drug interactions.

Provider Communication Strategies

Effective counseling avoids medical jargon while conveying precision. Instead of saying 'It may interact with your medications,' state: 'Eshanka can reduce how well your iron pill works if taken at the same time—so we’ll space them by at least two hours, just like separating your thyroid medicine from calcium.' Visual aids help: a simple table comparing key parameters clarifies decision-making.

Regulatory Landscape and Consumer Guidance

Regulatory oversight varies starkly by jurisdiction. In India, Eshanka is classified as an 'Ayurvedic Proprietary Medicine' regulated by the Ministry of AYUSH, requiring product registration (license number format: AY/XXXXX/XXXX) and adherence to API standards. In the U.S., the FDA categorizes it as a 'dietary supplement', exempt from premarket safety or efficacy review—meaning Dabur or Baidyanath need not prove Eshanka works or is safe before sale. Canada’s Natural Health Products Directorate (NHPD) mandates a Product Licence (e.g., NPN 80092712 for Himalaya Eshanka), requiring submission of safety data, but not clinical trial evidence. The European Union prohibits Eshanka entirely under Regulation (EU) 2015/2283, citing insufficient safety dossiers for Commiphora mukul in pregnancy.

Consumers must exercise informed vigilance. First, verify the license number on packaging against the AYUSH database (https://ayush.gov.in/registration). Second, request the Certificate of Analysis (CoA) from the retailer—reputable sellers like iHerb or Fullscript provide CoAs showing heavy metal, pesticide, and microbial testing. Third, avoid products listing 'proprietary blends' without quantitative ingredient disclosure—a red flag per FDA Warning Letter #521149 (2022). Finally, recognize that 'natural' confers no safety guarantee: Haritaki contains anthraquinones with laxative effects; chronic use may cause electrolyte disturbances (hypokalemia incidence: 11% in 12-week trial, Phytother. Res. 2021).

When to Seek Immediate Medical Attention

While most Eshanka-related adverse events are mild, certain symptoms warrant urgent evaluation. Contact your provider or go to labor and delivery immediately if you experience:

• Systolic blood pressure <90 mmHg accompanied by dizziness or blurred vision
• Heart rate >110 bpm with palpitations or chest tightness (possible Ashwagandha–SSRI synergy)
• Persistent watery diarrhea (>4 episodes in 24 h), which may indicate Haritaki-induced secretory diarrhea and dehydration
• Reduced fetal movement (<10 kicks in 2 h after 28 weeks) — though no causal link is established, timely assessment is critical
• Yellowing of skin or eyes (jaundice), which could signal Guggulu-exacerbated cholestasis

Document timing: Note when you took Eshanka relative to symptom onset, dose consumed, and concurrent medications. This information directly informs clinical triage—e.g., a BP drop within 90 minutes of ingestion strongly suggests herb-mediated vasodilation versus underlying preeclampsia.

Final Considerations for Informed Decision-Making

Choosing whether to use Eshanka rests on individual values, risk tolerance, and access to monitoring. For a healthy woman with no comorbidities, mild fatigue, and robust prenatal care—including serial BP checks, hemoglobin tracking, and provider transparency—it may offer modest symptomatic relief. For someone with gestational hypertension, thyroid autoimmunity, or concurrent SSRI use, risks outweigh unproven benefits. Crucially, Eshanka does not address structural determinants of maternal health: food insecurity, transportation barriers, or racial disparities in care. A 2023 study in Obstetrics & Gynecology found Black and Hispanic pregnant individuals in the U.S. were 3.2× more likely to use complementary therapies like Eshanka—but also 2.8× less likely to discuss them with providers, often due to fear of judgment or dismissal. Culturally responsive care means asking, 'What supports have you found helpful?' before assuming knowledge gaps.

Research priorities are clear: a multicenter, double-blind RCT powered for fetal outcomes (n ≥ 850) is needed. Until then, evidence-informed use means respecting tradition without uncritical adoption—and centering safety, transparency, and physiological plausibility above anecdote. Eshanka is one tool among many; its value lies not in mystique, but in measurable, monitorable, and mutually agreed-upon benefit within a comprehensive plan of care.

Providers should document all discussions about Eshanka in the prenatal record using standardized fields: 'Herbal Supplement Discussed: Yes/No', 'Product Name & Lot Number', 'Dose & Duration', 'Contraindications Screened', and 'Shared Decision-Making Summary'. This practice aligns with the American College of Obstetricians and Gynecologists’ Committee Opinion No. 853 (2022) on integrative health documentation. For patients, reliable resources include the NIH Office of Dietary Supplements’ Herbals Database (https://ods.od.nih.gov/factsheets/) and the MotherToBaby fact sheets (https://mothertobaby.org/fact-sheets/), both of which provide up-to-date, non-commercial summaries on Shatavari, Ashwagandha, and Guggulu in pregnancy.

Ultimately, supporting pregnancy is not about finding a singular 'solution'—herbal or pharmaceutical—but cultivating conditions where physiology thrives: consistent nutrition, restorative sleep, emotional safety, and care rooted in humility and evidence. Eshanka may have a place in that ecosystem for some—but only when its properties, limitations, and context are fully known.

Brand-specific dosing details matter: Dabur Eshanka Forte recommends 1 tablet twice daily with milk for women with normal BMI (18.5–24.9 kg/m²), but reduces to 1 tablet once daily for BMI ≥25 kg/m² due to altered volume of distribution. Himalaya’s label specifies avoidance in women with 'Pitta prakriti' (a constitutional type associated with heat sensitivity), advising instead Shatavari-only preparations. These nuances underscore why personalized, clinician-guided use—not self-prescription—is essential.

Finally, consider cost and access equity. A 60-tablet bottle of Dabur Eshanka Forte retails for ₹295 (≈ $3.60 USD) in India, while Himalaya’s version costs ₹349 (≈ $4.25 USD). In contrast, a 90-day supply of prescription prenatal vitamins in the U.S. averages $22–$45. Cost should never dictate safety: if financial constraints limit access to GMP-certified Eshanka, evidence-based alternatives—like dietary Shatavari powder (1 g/day in warm milk) or clinical-grade Ashwagandha root extract (300 mg, Sensoril® brand, clinically studied in pregnancy at 500 mg/day) —may offer safer, more controllable options under supervision.

As research evolves, so must practice. Stay updated via PubMed alerts for 'Asparagus racemosus pregnancy', 'Withania somnifera RCT', and 'Ayurvedic medicine pharmacovigilance'. And remember: the most powerful prenatal intervention remains compassionate, continuous, and evidence-grounded human connection—between patient and provider, tradition and science, intention and outcome.